Nuvectis Pharma, Inc. (NVCT)
- Previous Close
9.28 - Open
9.95 - Bid 9.83 x 200
- Ask 9.79 x 100
- Day's Range
9.29 - 10.31 - 52 Week Range
4.44 - 11.80 - Volume
149,745 - Avg. Volume
130,787 - Market Cap (intraday)
206.219M - Beta (5Y Monthly) -0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-1.13 - Earnings Date May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
www.nuvectis.comRecent News: NVCT
View More
Performance Overview: NVCT
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVCT
View MoreValuation Measures
Market Cap
206.22M
Enterprise Value
176.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.84
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.69%
Return on Equity (ttm)
-115.29%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-20.16M
Diluted EPS (ttm)
-1.13
Balance Sheet and Cash Flow
Total Cash (mrq)
29.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.67M
Research Analysis: NVCT
View MoreResearch Reports: NVCT
View MoreDaily – Vickers Top Insider Picks for 10/31/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/30/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/27/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 10/26/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.